AORTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
ARTIVION, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$22.28+0.50 (+2.30%)
Close on Oct 19, 2026
- Market cap
- $1.08B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
64.4%−1.9 pts over 5 years
Operating margin
7.6%+6.7 pts over 5 years
Net margin
2.2%+8.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +13.6% | +12.0% | +11.8% | +11.7% | |
| Gross profit | +14.2% | +12.0% | +11.1% | +12.1% | |
| Operating income | -13.2% | +75.9% | +69.1% | +20.2% | |
| Net income | – | – | – | +9.3% | |
| EPS, diluted | – | – | – | +4.1% | |
| Free cash flow | -92.4% | – | -30.1% | -20.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 5.9% | -5.4% | 2.7% | |
| Return on assets | 4.3% | -2.4% | 1.2% | |
| Current ratio | 4.89 | 3.88 | 3.53 | |
| Debt to equity | 0.34 | 0.89 | 0.48 | |
| Net debt to EBITDA | 0.47× | 9.92× | 2.67× | |
| Interest coverage | 7.3× | 0.1× | 1.3× | |
| Inventory turnover | 3.0× | 1.4× | 1.8× | |
| Capex to revenue | 3.4% | 2.9% | 8.8% | |
| Diluted shares | 33M | 38M | 47M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Artivion generated $88.68M from operations and spent $83.79M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$88.68M
Used
$83.79M
Capital expenditure$83.79M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin2.2%
×Asset turnover0.53×
×Equity multiplier2.31×
=Return on equity, FY20252.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 2.2% | 0.53× | 2.31× | 2.7% |
| FY2024 | -3.4% | 0.49× | 2.83× | -4.8% |
| FY2023 | -8.7% | 0.46× | 2.75× | -10.8% |
| FY2022 | -6.1% | 0.40× | 2.66× | -6.6% |
| FY2021 | -5.0% | 0.38× | 2.51× | -4.7% |
| FY2020 | -6.6% | 0.36× | 2.27× | -5.4% |
| FY2019 | 0.6% | 0.47× | 2.10× | 0.6% |
| FY2018 | -1.1% | 0.45× | 2.10× | -1.0% |
| FY2017 | 2.0% | 0.42× | 1.86× | 1.5% |
| FY2016 | 6.0% | 0.73× | 1.37× | 5.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$9.77M
- Cash generatingOperating cash flow above zero$39.88M
- Return on assets improvedROA up on the prior year-1.7% → 1.2%
- Earnings backed by cashOperating cash flow above net income$39.88M vs $9.77M
- Less leverageLong-term debt to assets fell39.8% → 24.3%
- Better liquidityCurrent ratio rose4.34 → 3.53
- No dilutionShare count did not rise42M → 47M
- Gross margin improvedGross margin up on the prior year64.03% → 64.40%
- More efficientAsset turnover rose0.49 → 0.56